Connection
Klane White to Receptor, Fibroblast Growth Factor, Type 3
This is a "connection" page, showing publications Klane White has written about Receptor, Fibroblast Growth Factor, Type 3.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.293 |
|
|
|
-
Savarirayan R, Hoover-Fong J, Irving M, Arundel P, de Bergua JM, Campeau PM, Candler T, Cocanougher BT, Cormier-Daire V, Edouard T, Fredwall SO, Harmatz P, Hoernschemeyer D, Irgens HU, Jamuar S, Kannu P, Legare JM, Leiva-Gea A, McDevitt H, Onesimo R, Phillips J, Del Pino M, Robinson ME, Rossi M, Skae M, Ward LM, White KK, Schmidt J, Lystig T, Salvatici A, Bai Y, Butler PW, van Veenhuyzen D, Rogoff D. Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia. N Engl J Med. 2026 Sep 03; 395(9):859-869.
Score: 0.241
-
MacCarrick G, Aradhya S, Bailey M, Chu D, Hunt A, Izzo E, Krakow D, Mackenzie W, Poll S, Raggio C, Shediac R, White KK, McLaughlin HM, Seratti G. Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: Results from the largest cohort to date. Am J Med Genet A. 2024 09; 194(9):e63646.
Score: 0.052
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|